Pfizer Inc. (PFE) Holdings Cut by Schroder Investment Management Group
Schroder Investment Management Group lessened its holdings in Pfizer Inc. (NYSE:PFE) by 9.3% in the third quarter, HoldingsChannel.com reports. The firm owned 13,044,866 shares of the biopharmaceutical company’s stock after selling 1,343,819 shares during the period. Pfizer accounts for 0.8% of Schroder Investment Management Group’s investment portfolio, making the stock its 15th largest holding. Schroder Investment Management Group’s holdings in Pfizer were worth $464,397,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. HL Financial Services LLC grew its stake in Pfizer by 1.1% in the 2nd quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock valued at $108,260,000 after purchasing an additional 35,744 shares during the period. Hartford Financial Management Inc. grew its stake in Pfizer by 10.8% in the 2nd quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock valued at $286,000 after purchasing an additional 835 shares during the period. Cadence Bank NA grew its stake in shares of Pfizer by 1.4% during the 2nd quarter. Cadence Bank NA now owns 99,962 shares of the biopharmaceutical company’s stock worth $3,358,000 after acquiring an additional 1,428 shares during the period. Majedie Asset Management Ltd grew its stake in shares of Pfizer by 7.9% during the 2nd quarter. Majedie Asset Management Ltd now owns 336,991 shares of the biopharmaceutical company’s stock worth $11,320,000 after acquiring an additional 24,531 shares during the period. Finally, Meag Munich Ergo Kapitalanlagegesellschaft MBH grew its stake in shares of Pfizer by 437.9% during the 3rd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 773,073 shares of the biopharmaceutical company’s stock worth $27,607,000 after acquiring an additional 629,361 shares during the period. Hedge funds and other institutional investors own 70.06% of the company’s stock.
In other Pfizer news, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the sale, the executive vice president now owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the sale, the insider now directly owns 103,458 shares in the company, valued at approximately $3,827,946. The disclosure for this sale can be found here. 0.06% of the stock is owned by company insiders.
Pfizer Inc. (NYSE PFE) opened at $34.66 on Tuesday. Pfizer Inc. has a 12 month low of $31.67 and a 12 month high of $39.43. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $206,600.00, a PE ratio of 9.85, a price-to-earnings-growth ratio of 1.93 and a beta of 0.94.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The business had revenue of $13.70 billion during the quarter, compared to the consensus estimate of $13.67 billion. During the same quarter last year, the company earned $0.47 EPS. The firm’s revenue was up .6% compared to the same quarter last year. equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer announced that its board has authorized a stock repurchase plan on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be paid a $0.34 dividend. The ex-dividend date is Thursday, February 1st. This represents a $1.36 annualized dividend and a yield of 3.92%. This is an increase from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio (DPR) is currently 38.64%.
COPYRIGHT VIOLATION WARNING: “Pfizer Inc. (PFE) Holdings Cut by Schroder Investment Management Group” was reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2018/02/13/pfizer-inc-pfe-holdings-cut-by-schroder-investment-management-group.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.